NCLT Approves Gland Chemicals-GCBC Pharma Demerger Scheme

NCLT Hyderabad approves a demerger scheme transferring Gland Chemicals' formulation business to GCBC Pharma with an appointed date of 01.04.2025.
Shareholders of Gland Chemicals will receive 1 GCBC Pharma equity share for every 1 share held in a 1:1 exchange ratio.
The approval is conditional on GCBC Pharma honoring all existing tax liabilities of Gland Chemicals, including a pending demand of ₹35.05 crore.
The scheme involves transferring assets worth ₹115.82 crore and liabilities of ₹294.73 crore of the formulation undertaking to GCBC Pharma.